ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1563

Risk of Overall Malignancies in Korean Patients with Primary Sjögren Syndrome

Hyoungyoung Kim1, Juyeon Kang1, Seongmi Choi2, Jinwook Kim3, Sun-Young Jung4, Eun Jin Jang5, Soo-Kyung Cho1 and Yoon-Kyoung Sung6, 1Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 2Statistics, Kyungpook National University, Daegu, Korea, Republic of (South), 3Department of Statistics, Kyungpook National University, Daegu, Korea, Republic of (South), 4College of Pharmacy, Chung-Ang University, Seoul, Korea, Republic of (South), 5Information Statistics, Andong National University, Andong-si, Korea, Republic of (South), 6Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Malignancy and risk, Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Sjögren's Syndrome – Basic and Clinical Science Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: A significant association has been found between primary Sjögren syndrome (pSS) and non-hodgkin’s lymphoma (NHL), but few studies have been conducted to explore the association of pSS with the risk of overall malignancies. We conducted the study to investigate the association between pSS and the risks of malignancy including overall and site-specific malignancies.

Methods: Using the Korean nationwide claims database, a retrospective cohort of prevalent pSS patients between January 2012 and December 2014 was constructed. After exclusion of patients who had a previous history of malignancy, each patient was observed up to the development of any malignancy, or December 2015. The crude incidence rate (IR) of overall and site-specific malignancies in patients with pSS over 19 years old was estimated. To assess excess occurrence of overall malignancies in patients over 50 years of age, we calculated standardized incidence ratios (SIR) by dividing the observed number of malignancies of pSS patients by the expected number of malignancies calculated from the accumulated person-years and the age-, sex-, calendar period-specific malignancy incidence rates of knee OA patients.

Results: A total of 9,826 patients with pSS over 19 years of age were enrolled in this study. During 30,082 person-years (PYs) of observation, 424 cases of solid malignancies (IR 140.6/10,000 PYs) and 62 cases of hematologic malignancies (IR 20.2/10,000 PYs) occurred in adult pSS patients. For patients with pSS aged over 50 (n=6,359), 314 cases of solid malignancy (IR 160.8/10,000 PYs) and 42 cases of hematologic malignancies (IR 21.0/10,000 PYs) were diagnosed during 19,474 PYs of follow-up. For the patients over 50 years of age, the SIRs of overall (1.29, 95% CI 1.16-1.43), solid (1.21, 95% CI 1.07-1.34), and hematologic malignancies (4.54, 95% CI 3.17-5.92), in patients with pSS increased compared to those of OA patients (n=5,476,302). Patients with pSS were at a significantly increased risk of non-hodgkin’s lymphoma (SIR 5.75, 95% CI 3.58-7.92), multiple myeloma (SIR 4.88, 95% CI 2.00-7.76), lung cancer (SIR 1.59, 95% CI 1.08-2.09), and lip and oropharyngeal cancer (SIR 4.16, 95% CI 1.90-6.42).

Conclusion: Our study indicates that pSS is significantly associated with increased risks of overall malignancy, NHL, multiple myeloma, lung cancer, and lip and oropharyngeal cancer.


Disclosure: H. Kim, None; J. Kang, None; S. Choi, None; J. Kim, None; S. Y. Jung, None; E. J. Jang, None; S. K. Cho, None; Y. K. Sung, None.

To cite this abstract in AMA style:

Kim H, Kang J, Choi S, Kim J, Jung SY, Jang EJ, Cho SK, Sung YK. Risk of Overall Malignancies in Korean Patients with Primary Sjögren Syndrome [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/risk-of-overall-malignancies-in-korean-patients-with-primary-sjogren-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-overall-malignancies-in-korean-patients-with-primary-sjogren-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology